Stay updated on IMRT & Nivolumab for Recurrent Head & Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the IMRT & Nivolumab for Recurrent Head & Neck Cancer Clinical Trial page.

Latest updates to the IMRT & Nivolumab for Recurrent Head & Neck Cancer Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedA new Revision: v3.4.2 was added and the earlier funding-status notice (v3.4.1) was removed; these are administrative site updates that do not affect the trial details or displayed study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedNotice added about government funding and operating status; site version updated to v3.4.1, replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded a glossary toggle and updated footer metadata with 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. Removed the older 'Last Update Submitted that met QC Criteria' label, 'No FEAR Act data', and 'Revision: v3.3.4' from the page.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision: v3.3.4 was added and v3.3.3 was removed, reflecting a minor site version update. This update does not affect study details or results; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedLocations section updated to include Georgia, Ohio, and Wisconsin. HHS Vulnerability Disclosure and related location headings were removed; the page revision now shows v3.3.3.SummaryDifference0.4%

Stay in the know with updates to IMRT & Nivolumab for Recurrent Head & Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMRT & Nivolumab for Recurrent Head & Neck Cancer Clinical Trial page.